Skip to main content
Fig. 1 | BMC Complementary and Alternative Medicine

Fig. 1

From: Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model

Fig. 1

The inhibitory effect of BP3B on in vivo tumor growth in PDTX model. Patient-derived colon tumors were subcutaneously established in BALB/c nude mice. Representative PDTX samples were resected on day 21 (five tumors per group) showing the difference in tumor volumes between vehicle (0.5% Na-CMC), extracts (250 and 500 mg/kg) and oxaliplatin (5 mg/kg) (a). When the tumors reached 100-200 mm3 in size, mice were treated with drugs for 3 weeks. Tumor sizes were measured every 3 days using a caliper and tumor volumes were calculated (b) and body weight (c). ** p < 0.01 and *** p < 0.001

Back to article page